Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01245673 · ClinicalTrials.gov registry record · Phase 2
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01245673: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT01245673 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01245673, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
One purpose of this study is to find out if a new combination of immune system treatments (MAGE-A3 vaccine plus activated T-cells) will allow the body to build up protection ("immunity") against the myeloma cells. A second purpose is to find out how well this combination of immune system treatments is able to control the myeloma.
Primary Outcome
To determine whether lenalidomide maintenance plus the late booster immunizations leads to improved myeloma clinical responses between day 180 and day 100 post-transplant.
Interventions
- BIOLOGICAL Prevnar- Pneumococcal Conjugate Vaccine (PCV)
- OTHER Activated/costimulated autologous T-cell
- DRUG Revlamid® (Lenalidomide)
- BIOLOGICAL MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-05-10 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
What the finished NCT01245673 record still lists
NCT01245673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 4 interventions - of which Prevnar- Pneumococcal Conjugate Vaccine (PCV) is the first listed.
NCT01245673 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01245673 about?
NCT01245673 is a clinical study titled "Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma". One purpose of this study is to find out if a new combination of immune system treatments (MAGE-A3 vaccine plus activated T-cells) will allow the body to build up protection ("immunity") against the myeloma cells. A second purpose is to find out how well this combination of immune system treatments ...
What is the current status of trial NCT01245673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2011-05-10. Estimated completion is 2018-12.
What interventions are being tested in trial NCT01245673?
The interventions under investigation include: Prevnar- Pneumococcal Conjugate Vaccine (PCV) (BIOLOGICAL), Activated/costimulated autologous T-cell (OTHER), Revlamid® (Lenalidomide) (DRUG), MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01245673?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01245673's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI